Gossamer Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
GOSS$10.65+9.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and par value amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $37,732 | $46,074 |
| Marketable securities | 99,200 | 248,444 |
| Receivable from contracts with collaborators | 12,227 | 5,338 |
| Prepaid expenses and other current assets | 18,485 | 10,032 |
| Total current assets | 167,644 | 309,888 |
| Property and equipment, net | 64 | 10 |
| Operating lease right-of-use assets | 4,133 | 5,111 |
| Other assets | 408 | 283 |
| Total assets | $172,249 | $315,292 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $5,959 | $2,319 |
| Accrued research and development expenses | 21,662 | 10,455 |
| Current contract liabilities | 19,987 | 17,050 |
| Accrued expenses and other current liabilities | 15,827 | 15,186 |
| Total current liabilities | 63,435 | 45,010 |
| Long-term convertible senior notes | 198,508 | 197,523 |
| Operating lease liabilities - long-term | 3,460 | 4,398 |
| Long-term contract liabilities | 29,606 | 38,869 |
| Total liabilities | 295,009 | 285,800 |
| Commitments and contingencies (Note 11) | ||
| Stockholders' equity (deficit) | ||
| Common stock, $0.0001 par value; 700,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 233,677,057 shares issued and outstanding as of December 31, 2025, and 226,604,138 shares issued and outstanding as of December 31, 2024 | 24 | 23 |
| Additional paid-in capital | 1,321,303 | 1,296,848 |
| Accumulated deficit | (1,438,938) | (1,268,568) |
| Accumulated other comprehensive income (loss) | (5,149) | 1,189 |
| Total stockholders' equity (deficit) | (122,760) | 29,492 |
| Total liabilities and stockholders' equity (deficit) | $172,249 | $315,292 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.